Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Genzyme General

This article was originally published in The Gray Sheet

Executive Summary

Spin-off of surgical products business Genzyme Surgical Products will be effective with the commencement of public trading on the Nasdaq exchange on June 28 under the ticker symbol GZSP. A tax-free dividend of about 0.17967 shares of Genzyme Surgical stock will be distributed for each share of Genzyme General held by shareholders of record on June 14. Upon formation, Genzyme Surgical, which will have about 14.8 mil. shares outstanding after the distribution, will be funded with $150 mil. in cash from Genzyme General. The spin-off will allow Genzyme General to focus more closely on therapeutics and stimulate investment for the development of surgical products ("The Gray Sheet" May 24, p. 21)

Latest Headlines
See All
UsernamePublicRestriction

Register

MT011833

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel